Aktieanalys

Magle Chemoswed Q2: Convincing and advancing - Redeye

Redeye Publicerad: 19 Jul 08:51

Redeye provides a research update following the Q2 report recently published by Magle. The second quarter of 2024 for Magle was primarily marked by the merger and acquisitions of Amniotics and pK Chemicals. We believe that both of these are poised to generate long-term shareholder value for Magle. Furthermore, the company reported a slightly higher sales figure than expected, a 21% y/y growth, with an increase in revenue from its DSM products. We raise our fair value range (SEK30 – SEK70) with a new base case valuation of SEK50.

Länk till analysen i sin helhet: https://www.redeye.se/research/1023694/magle-chemoswed-q2-convincing-and-advancing?utm_source=finwire&utm_medium=RSS

Nyheter om Magle Chemoswed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!